In one paragraphArticle in Cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
13 authors.
Justin D ClubbDepartment of Chemical and Biomolecular Engineering, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0001-9819-6619 Ryan M ShihMolecular Biology Institute, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0002-3570-867X Torahito A GaoDepartment of Chemical and Biomolecular Engineering, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0003-4333-5305 Amanda ShaferDepartment of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0003-2931-1569 Shreya VajragiriDepartment of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, Los Angeles, California.ORCID 0009-0005-5825-7073 Katrina LamNeuroscience Interdepartmental Program, University of California, Los Angeles, Los Angeles, California.ORCID 0009-0006-9537-177X Sohan TalluriDepartment of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0003-1140-1929 Amber BourenDepartment of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, Los Angeles, California.ORCID 0009-0004-0385-3276 Christine E BrownDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center and Beckman Research Institute, Duarte, California.ORCID 0000-0003-4915-8207 Pedro RuivoComparative Pathology Laboratory, University of California Davis School of Veterinary Medicine; Davis, California.ORCID 0000-0002-5419-4790 Robert M PrinsDepartment of Neurosurgery, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0002-6282-6583 Yvonne Y ChenDepartment of Chemical and Biomolecular Engineering, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0002-5583-119X Funding
UCLA-Caltech Medical Scientist Training ProgramT32GM008042 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AJIJOLA, OLUJIMI A, DAWSON, DAVID WAYNE · 1985 to 2023
$29.9MUCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2MUCLA Tumor Immunology Training ProgramT32CA009120 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Steven M. Dubinett, MICHAEL A TEITELL · 1985 to 2026
$10.3MUCLA-Caltech Medical Scientist Training ProgramT32GM152342 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Olujimi A Ajijola, David Wayne Dawson · 2024 to 2026
$5.3MNeoadjuvant checkpoint blockade for recurrent glioblastomaR01CA267726 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Robert M Prins · 2022 to 2026
$2.4MProgramming multi-pronged immune response to glioblastoma with IL-13Ra2/TGF-b CAR-T cell therapy.R01NS126849 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2023 to 2026
$2.4MCancer Research Institute (CRI) Lloyd J. Old STAR AwardNational Cancer Institute (NCI) 1R01CA267726-01National Cancer Institute (NCI) 2P50CA211015-06National Institute of Neurological Disorders and Stroke (NINDS) 1R01NS126849National Institutes of Health (NIH) 2T32CA009120-46A1National Institutes of Health (NIH) 5T32CA009120-44National Institutes of Health (NIH) 5T32CA009120-45National Science Foundation Graduate Research Fellowship Program (GRFP) DGE-2034835NCI NIH HHS P50 CA211015NCI NIH HHS R01 CA267726NCI NIH HHS T32 CA009120NIGMS NIH HHS T32 GM008042NIGMS NIH HHS T32 GM152342NINDS NIH HHS R01 NS126849University of California Los Angeles Whitcome Fellowship
6 · The paper itselfAbstract
Chimeric antigen receptor (CAR) T-cell therapy has shown early promise against glioblastoma, which lacks effective treatment options. However, two key challenges curtail efficacy: tumor-antigen heterogeneity and an immunosuppressive tumor microenvironment. CAR T cells engineered to secrete combinations of immunomodulatory proteins can reverse immune suppression and engage endogenous immunity. Through head-to-head in vivo comparisons of potentially synergistic armor combinations, we demonstrated that T cells expressing a CAR plus IL12 and the decoy-resistant form of IL18 (CAR-12.DR18 T cells) show strong efficacy against antigen-heterogeneous glioma in immunocompetent mice. Robust antitumor efficacy with effective toxicity mitigation was achieved via combined administration of CAR-12.DR18 T cells with CAR T cells that secrete an anti-vascular endothelial growth factor (anti-VEGF) single-chain variable fragment (scFv). This combination therapy presents a clinically applicable strategy to overcome key barriers to the effective treatment of glioblastoma. SIGNIFICANCE: CAR-T cells armored with cytokines and anti-VEGF single-chain variable fragments can control orthotopic, antigen-heterogeneous glioma with minimal toxicity, providing a therapeutic strategy for glioblastoma patients in urgent need of efficacious treatments.
Indexed as
Brain NeoplasmsGliomaImmunotherapy, AdoptiveReceptors, Chimeric AntigenT-LymphocytesAnimalsAntigens, NeoplasmCell Line, TumorHumansInterleukin-12MiceSingle-Chain AntibodiesTumor MicroenvironmentVascular Endothelial Growth Factor AXenograft Model Antitumor AssaysAntigens, NeoplasmInterleukin-12Receptors, Chimeric AntigenSingle-Chain AntibodiesVascular Endothelial Growth Factor A
Identifiers
PMID42159488
PMCPMC13263108
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390